Information letter to health care professionals on the safe use of the medicinal products ATOVAX®, TAIGERON®, OZERLIK®, POLIMIK® (systemic and inhaled fluoroquinolones: warning about the risk of aortic aneurysm and/or dissection)

17.01.2024 Updated 01.02.2024 1000 views

Information letter to healthcare professionals regarding the safety of use of the medicinal products ATOVAX®, TAIGERON®, OZERLIK®, POLIMIK® (systemic and inhaled fluoroquinolones: warning about the risk of aortic aneurysm and/or dissection)PDF · 170 KB

Завантажити

Information letter to health care professionals on the safe use of the medicinal products ATOVAX®, TAIGERON®, OZERLIK®, POLIMIK® (systemic and inhaled fluoroquinolones: warning about the risk of aortic aneurysm and/or dissection)

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Information letter to health care professionals on the safe use of the medicinal products ATOVAX®, TAIGERON®, OZERLIK®, POLIMIK® (systemic and inhaled fluoroquinolones: warning about the risk of aortic aneurysm and/or dissection)

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration